Skip to main content
OpenTrials
Completed

NCT Number: NCT03846752

Complex Large-bore Radial Percutaneous Coronary Intervention (PCI) Trial

The COLOR trial is a Multicenter Randomized trial. Patients are eligible for study participation when PCI is indicated for complex coronary lesions. If patients comply with inclusion and exclusion and provide written informed consent they will be randomized in a 1:1 fashion between the two study treatments, (7 Fr. radial access with a Glideslender sheath or 7 Fr. femoral access with a standard femoral sheath) , in a 1:1 ratio.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ZNA Middelheim, Antwerp, Belgium

Loading trial locations.

About this study

The COLOR trial is a Multicenter Randomized trial. Patients are eligible for study participation when PCI is indicated for complex coronary lesions. If patients comply with inclusion and exclusion and provide written informed consent they will be randomized in a 1:1 fashion between the two study treatments, (7 Fr. radial access with a Glideslender sheath or 7 Fr. femoral access with a standard femoral sheath) , in a 1:1 ratio.

During hospitalization (before discharge) the access site(s) will be checked for bleeding and vascular complications. All access sites should be checked for absent pulsations and hematomas and the size should be defined (length and width, cm) and accompanied complaints. Radial artery occlusion should be checked with the reverse Barbeau test. The femoral access site should be checked for murmurs and absence of pulsations. Ultrasound or Doppler of the access sites should be performed in those patients with suspected radial or femoral occlusion and the presence of other vascular complications, like (pseudo) aneurysms or arteriovenous (AV) fistula within 1 month.

Patient-reported extremity dysfunction will be evaluated at baseline (before the procedure) and 1-month follow-up. Upper extremity function will be evaluated with the Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) and lower extremity function with Lower Extremity Functional Scale questionnaire (LEFS). The occurrence of Major Adverse Cardiac Events (MACE) will be evaluated at discharge and 1-month follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Use of 7 Fr guiding catheter is indicated for complex PCI, according to the expertise of the treating physician.
  • Age 18 years or older.

Exclusion criteria

  • Inability to obtain informed consent
  • contra-indication for radial or femoral access
  • Cardiogenic shock
  • ST-elevation myocardial infarction

Treatment and study plan

radial artery access for complex PCI

Procedure

Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.

femoral artery access for complex PCI

Procedure

Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.

Primary outcomes

  1. The primary endpoint is defined as BARC 2,3 and 5 (Bleeding Academic Research Consortium) bleeding or vascular complication related to the randomized access site (during hospitalization).

    Time frame: PCI procedure till patients is discharged from the hospital, with a maximum of 30 days

    The primary endpoint is defined as BARC 2,3 and 5 bleeding or vascular complication related to the randomized access site (during hospitalization).

Secondary outcomes

  1. Non-access site related BARC 2,3 and 5 bleeding and/or vascular complications (hospitalization)

    Time frame: PCI procedure till patients is discharged from the hospital, with a maximum of 30 days

    Non-access site related BARC 2,3 and 5 bleeding and/or vascular complications (hospitalization)

  2. MACE (hospitalization and 1-month)

    Time frame: PCI procedure till 30 days after PCI procedure

    MACE: Composite of death, myocardial infarction and repeat revascularization

  3. Procedural success

    Time frame: during PCI procedure

    Successful PCI of the target lesion with a residual stenosis of less than 20%

  4. procedural time

    Time frame: during PCI procedure

    Procedural time from puncture to end procedure (in minutes)

  5. fluoroscopy time

    Time frame: during PCI procedure

    fluoroscopy time (in seconds)

  6. contrast use

    Time frame: during PCI procedure

    Contrast volume used (in ml)

  7. crossover rate

    Time frame: during PCI procedure

    Failure to complete the procedure through the randomized access site, requiring conversion from radial to femoral access or vice versa for procedure completion

Sponsors and collaborators

Lead sponsor

Maatschap Cardiologie Zwolle

Other

Collaborators

  • Terumo Europe N.V.

Registry information

Official study title

Complex Large-bore Radial PCI Trial Randomized Trial Reducing Access Site Complications With Slender Technology for Complex PCI

Acronym: Color

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Feb 20, 2019
Registry last updated
Aug 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.